Vaccines for melanoma - 01/09/11

Doi : 10.1016/S0733-8635(02)00038-4

Jean-Claude Bystryn, MD
The Ronald O. Perelman Department of Dermatology and Melanoma Program and Melanoma Immunotherapy Clinic, Kaplan Comprehensive Cancer Center, New York University School of Medicine, 35 East 35th Street, Suite 208, New York, NY 10016, USA

Mappa

The rationale for using vaccines to treat melanoma

What is required for a melanoma vaccine to work?

The number of antigens required to induce effective protective immunity

HLA restriction of vaccine-induced immune responses

Heterogeneity in patient's ability to develop immune responses to the same antigen

The advantages of polyvalent vaccines

Strategies used to construct melanoma vaccines and their relative advantages and disadvantages

Nonpurified vaccines

Vaccines prepared from pure antigens

Vaccines prepared from partially purified antigens

Adjuvants

Results of clinical trials of melanoma vaccines

Who is a candidate for melanoma vaccine treatment?

What to tell patients

What vaccine should be recommended?

Summary

This article is supported in part by National Institutes of Health grant No. 1 R01 CA89270 and by grants from the Rose M. Badgeley Residual trust and the Catherine and Henry Gaisman Foundation.

Esportazione

Vol 20 - N° 4

P. 717-725 - ottobre 2002 Ritorno al numero

Articolo precedente

Radiation therapy of malignant melanoma
Jay S Cooper

| Articolo seguente

Unusual melanoma types
Jason K Rivers

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

connettersi o creare un account

Vaccines for melanoma - 01/09/11

Mappa

Citazioni Export

File

Contenuto

Il mio account

Aide & support

Dichiarazione CNIL